Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 71 | 2024 | 5663 | 4.460 |
Why?
|
Graft vs Host Disease | 41 | 2024 | 3028 | 3.070 |
Why?
|
Epstein-Barr Virus Infections | 10 | 2024 | 611 | 2.800 |
Why?
|
Lymphoproliferative Disorders | 6 | 2024 | 533 | 2.180 |
Why?
|
Cytomegalovirus Infections | 7 | 2024 | 831 | 2.070 |
Why?
|
Severe Combined Immunodeficiency | 10 | 2024 | 226 | 1.600 |
Why?
|
Transplantation, Homologous | 33 | 2024 | 4808 | 1.520 |
Why?
|
Cytomegalovirus | 6 | 2024 | 755 | 1.510 |
Why?
|
Transplantation Conditioning | 24 | 2024 | 1588 | 1.490 |
Why?
|
Herpesvirus 4, Human | 8 | 2024 | 1078 | 1.290 |
Why?
|
Adoptive Transfer | 5 | 2022 | 819 | 1.260 |
Why?
|
Lymphocyte Depletion | 8 | 2020 | 602 | 1.070 |
Why?
|
T-Lymphocytes | 27 | 2024 | 10188 | 1.070 |
Why?
|
Organ Transplantation | 4 | 2024 | 1154 | 0.950 |
Why?
|
Leukemia | 5 | 2024 | 1522 | 0.940 |
Why?
|
Acetates | 1 | 2024 | 321 | 0.830 |
Why?
|
Transplants | 1 | 2022 | 206 | 0.680 |
Why?
|
Thymus Gland | 6 | 2004 | 1241 | 0.670 |
Why?
|
Leukemia, Myeloid, Acute | 9 | 2023 | 3610 | 0.590 |
Why?
|
Quinazolines | 1 | 2024 | 1371 | 0.580 |
Why?
|
Busulfan | 6 | 2024 | 258 | 0.550 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 1549 | 0.550 |
Why?
|
beta-Thalassemia | 5 | 2024 | 236 | 0.550 |
Why?
|
Lymphoma | 4 | 2024 | 1901 | 0.540 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 4 | 2020 | 263 | 0.520 |
Why?
|
Immunotherapy, Adoptive | 7 | 2020 | 1463 | 0.500 |
Why?
|
Antiviral Agents | 4 | 2024 | 3066 | 0.490 |
Why?
|
Viremia | 5 | 2023 | 707 | 0.480 |
Why?
|
Fanconi Anemia | 4 | 2023 | 324 | 0.470 |
Why?
|
Cord Blood Stem Cell Transplantation | 5 | 2015 | 305 | 0.440 |
Why?
|
Antilymphocyte Serum | 6 | 2024 | 483 | 0.440 |
Why?
|
Hematologic Neoplasms | 7 | 2023 | 1890 | 0.440 |
Why?
|
Granulomatous Disease, Chronic | 2 | 2024 | 173 | 0.420 |
Why?
|
T-Lymphocytes, Cytotoxic | 6 | 2021 | 1766 | 0.410 |
Why?
|
Myelodysplastic Syndromes | 6 | 2024 | 1393 | 0.400 |
Why?
|
Mesenchymal Stem Cell Transplantation | 4 | 2020 | 499 | 0.400 |
Why?
|
Myeloablative Agonists | 6 | 2020 | 209 | 0.380 |
Why?
|
Hematopoietic Stem Cells | 7 | 2024 | 3396 | 0.360 |
Why?
|
Child | 52 | 2024 | 80086 | 0.340 |
Why?
|
Vidarabine | 5 | 2018 | 336 | 0.340 |
Why?
|
Histocompatibility Testing | 6 | 2019 | 719 | 0.310 |
Why?
|
Adenoviridae Infections | 2 | 2020 | 93 | 0.310 |
Why?
|
Virus Diseases | 3 | 2022 | 719 | 0.310 |
Why?
|
CD4-Positive T-Lymphocytes | 5 | 2022 | 4369 | 0.310 |
Why?
|
Antigen-Presenting Cells | 1 | 2011 | 964 | 0.300 |
Why?
|
Tissue Donors | 7 | 2024 | 2319 | 0.290 |
Why?
|
T-Lymphocyte Subsets | 3 | 2004 | 1805 | 0.280 |
Why?
|
Kidney Transplantation | 1 | 2022 | 4226 | 0.280 |
Why?
|
Humans | 103 | 2024 | 760437 | 0.270 |
Why?
|
Acute Disease | 10 | 2024 | 7230 | 0.260 |
Why?
|
Child, Preschool | 34 | 2024 | 42209 | 0.250 |
Why?
|
Chimerism | 3 | 2021 | 155 | 0.240 |
Why?
|
Cyclophosphamide | 4 | 2023 | 2218 | 0.240 |
Why?
|
Receptors, Interferon | 1 | 2024 | 116 | 0.230 |
Why?
|
Viral Matrix Proteins | 2 | 2015 | 196 | 0.220 |
Why?
|
Candidiasis, Chronic Mucocutaneous | 1 | 2023 | 19 | 0.220 |
Why?
|
Antigens, Viral | 2 | 2019 | 987 | 0.220 |
Why?
|
Mesenchymal Stem Cells | 3 | 2020 | 1636 | 0.220 |
Why?
|
Interleukin Receptor Common gamma Subunit | 2 | 2018 | 85 | 0.210 |
Why?
|
Infant | 25 | 2024 | 36183 | 0.210 |
Why?
|
Janus Kinase 3 | 2 | 2018 | 76 | 0.210 |
Why?
|
Recurrence | 4 | 2024 | 8466 | 0.210 |
Why?
|
Integrins | 2 | 2004 | 834 | 0.210 |
Why?
|
Lymphopenia | 1 | 2024 | 280 | 0.190 |
Why?
|
Cell Movement | 4 | 2003 | 5198 | 0.190 |
Why?
|
Young Adult | 27 | 2024 | 59068 | 0.190 |
Why?
|
Hemoglobinopathies | 1 | 2021 | 99 | 0.190 |
Why?
|
Hemoglobinuria, Paroxysmal | 2 | 2011 | 95 | 0.190 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2022 | 313 | 0.190 |
Why?
|
Globins | 1 | 2022 | 403 | 0.180 |
Why?
|
Agammaglobulinemia | 1 | 2022 | 173 | 0.180 |
Why?
|
Opportunistic Infections | 1 | 2023 | 376 | 0.180 |
Why?
|
Antigens, CD34 | 5 | 2022 | 658 | 0.180 |
Why?
|
Retrospective Studies | 28 | 2024 | 80430 | 0.180 |
Why?
|
Disease-Free Survival | 7 | 2020 | 6813 | 0.180 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2022 | 251 | 0.170 |
Why?
|
Adenylate Kinase | 1 | 2020 | 102 | 0.170 |
Why?
|
Wiskott-Aldrich Syndrome | 1 | 2020 | 130 | 0.170 |
Why?
|
Leukopenia | 1 | 2020 | 213 | 0.170 |
Why?
|
Adolescent | 36 | 2024 | 88196 | 0.170 |
Why?
|
Wiskott-Aldrich Syndrome Protein | 1 | 2020 | 160 | 0.170 |
Why?
|
Cadherins | 1 | 2004 | 904 | 0.170 |
Why?
|
Adult | 38 | 2024 | 220781 | 0.160 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2024 | 9267 | 0.160 |
Why?
|
Male | 50 | 2024 | 360035 | 0.160 |
Why?
|
Lentivirus | 1 | 2022 | 508 | 0.160 |
Why?
|
Salvage Therapy | 3 | 2019 | 1264 | 0.150 |
Why?
|
Bone Marrow Transplantation | 3 | 2018 | 2693 | 0.150 |
Why?
|
Bone Marrow Cells | 2 | 2023 | 2416 | 0.150 |
Why?
|
Extracellular Matrix Proteins | 1 | 2002 | 828 | 0.150 |
Why?
|
Standard of Care | 1 | 2022 | 550 | 0.150 |
Why?
|
Neoplasm, Residual | 3 | 2024 | 1008 | 0.150 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 223 | 0.150 |
Why?
|
Alleles | 3 | 2024 | 6908 | 0.150 |
Why?
|
Introns | 1 | 2020 | 981 | 0.140 |
Why?
|
Heterozygote | 1 | 2024 | 2798 | 0.140 |
Why?
|
Survival Rate | 7 | 2020 | 12698 | 0.140 |
Why?
|
Gene Transfer Techniques | 2 | 2014 | 1205 | 0.140 |
Why?
|
Female | 45 | 2024 | 391875 | 0.140 |
Why?
|
Anemia, Sickle Cell | 2 | 2024 | 1063 | 0.140 |
Why?
|
Antigens, CD19 | 1 | 2019 | 425 | 0.140 |
Why?
|
Hematologic Diseases | 2 | 2020 | 496 | 0.140 |
Why?
|
Anemia, Aplastic | 1 | 2018 | 228 | 0.130 |
Why?
|
Phosphoproteins | 2 | 2015 | 2444 | 0.130 |
Why?
|
Treatment Outcome | 16 | 2024 | 64591 | 0.130 |
Why?
|
HLA Antigens | 4 | 2016 | 1371 | 0.130 |
Why?
|
Myeloproliferative Disorders | 1 | 2022 | 611 | 0.130 |
Why?
|
Mycophenolic Acid | 2 | 2015 | 347 | 0.130 |
Why?
|
Genetic Vectors | 3 | 2022 | 3392 | 0.130 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2018 | 1405 | 0.120 |
Why?
|
Survival Analysis | 10 | 2020 | 10075 | 0.120 |
Why?
|
Cytomegalovirus Retinitis | 1 | 2015 | 56 | 0.120 |
Why?
|
CD4 Lymphocyte Count | 1 | 2021 | 2569 | 0.120 |
Why?
|
Lymphocyte Transfusion | 1 | 2015 | 232 | 0.120 |
Why?
|
Neoplasms | 1 | 2023 | 22083 | 0.110 |
Why?
|
Neonatal Screening | 3 | 2024 | 597 | 0.110 |
Why?
|
Down Syndrome | 1 | 2022 | 898 | 0.110 |
Why?
|
Lung Diseases | 1 | 2024 | 1909 | 0.110 |
Why?
|
beta-Globins | 1 | 2014 | 111 | 0.110 |
Why?
|
Interleukins | 1 | 2018 | 782 | 0.110 |
Why?
|
Infection Control | 1 | 2020 | 985 | 0.110 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2014 | 225 | 0.100 |
Why?
|
Remission Induction | 2 | 2016 | 2394 | 0.100 |
Why?
|
Skin Diseases | 1 | 2021 | 1090 | 0.100 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2023 | 4575 | 0.100 |
Why?
|
Immunocompromised Host | 1 | 2017 | 855 | 0.100 |
Why?
|
Cell Differentiation | 7 | 2018 | 11526 | 0.100 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2019 | 5292 | 0.100 |
Why?
|
Dyskeratosis Congenita | 1 | 2012 | 73 | 0.100 |
Why?
|
Transplantation Chimera | 2 | 2004 | 594 | 0.100 |
Why?
|
Chickenpox Vaccine | 1 | 2011 | 40 | 0.100 |
Why?
|
Meningococcal Infections | 1 | 2011 | 78 | 0.090 |
Why?
|
Keratinocytes | 1 | 2015 | 790 | 0.090 |
Why?
|
Repressor Proteins | 1 | 2022 | 2978 | 0.090 |
Why?
|
Meningococcal Vaccines | 1 | 2011 | 94 | 0.090 |
Why?
|
Genetic Association Studies | 1 | 2020 | 2723 | 0.090 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2019 | 2531 | 0.090 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 381 | 0.090 |
Why?
|
Exanthema | 1 | 2015 | 504 | 0.090 |
Why?
|
Infant, Newborn | 8 | 2024 | 26280 | 0.090 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2014 | 617 | 0.090 |
Why?
|
Herpesvirus 3, Human | 1 | 2011 | 159 | 0.090 |
Why?
|
Hodgkin Disease | 1 | 2017 | 1378 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 11729 | 0.080 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2010 | 326 | 0.080 |
Why?
|
Melphalan | 3 | 2017 | 420 | 0.080 |
Why?
|
Animals, Newborn | 2 | 2004 | 2676 | 0.080 |
Why?
|
Lymphocyte Count | 2 | 2022 | 778 | 0.080 |
Why?
|
Radiation Chimera | 2 | 2004 | 216 | 0.070 |
Why?
|
Prognosis | 5 | 2020 | 29551 | 0.070 |
Why?
|
Mice | 8 | 2023 | 81402 | 0.070 |
Why?
|
Gastrointestinal Tract | 1 | 2013 | 831 | 0.070 |
Why?
|
Middle Aged | 18 | 2024 | 220382 | 0.070 |
Why?
|
Mutation | 4 | 2024 | 30025 | 0.070 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2020 | 3072 | 0.070 |
Why?
|
Immunization | 2 | 2011 | 1226 | 0.070 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2013 | 1373 | 0.070 |
Why?
|
Tissue Plasminogen Activator | 1 | 2011 | 1163 | 0.060 |
Why?
|
Canada | 2 | 2023 | 2119 | 0.060 |
Why?
|
Transduction, Genetic | 2 | 2022 | 901 | 0.060 |
Why?
|
Receptors, Cell Surface | 1 | 2014 | 2819 | 0.060 |
Why?
|
Multicenter Studies as Topic | 1 | 2010 | 1703 | 0.060 |
Why?
|
B-Lymphocytes | 2 | 2018 | 4748 | 0.060 |
Why?
|
Animals | 12 | 2023 | 168253 | 0.060 |
Why?
|
Hepatitis B Vaccines | 1 | 2006 | 185 | 0.060 |
Why?
|
Lymphocytes, Null | 1 | 2004 | 13 | 0.060 |
Why?
|
Cell Division | 2 | 2004 | 4461 | 0.060 |
Why?
|
Cell Adhesion | 2 | 2002 | 3088 | 0.060 |
Why?
|
Animals, Congenic | 1 | 2004 | 26 | 0.060 |
Why?
|
Genetic Variation | 1 | 2020 | 6570 | 0.060 |
Why?
|
Adenoviridae | 2 | 2020 | 1084 | 0.060 |
Why?
|
Thymus Extracts | 1 | 2004 | 2 | 0.060 |
Why?
|
Receptors, Interleukin-7 | 1 | 2004 | 40 | 0.060 |
Why?
|
Steroids | 2 | 2020 | 928 | 0.060 |
Why?
|
Aged | 12 | 2024 | 168840 | 0.060 |
Why?
|
Viral Load | 3 | 2020 | 3329 | 0.060 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 2004 | 221 | 0.060 |
Why?
|
Bone Marrow | 3 | 2024 | 2907 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2020 | 7849 | 0.060 |
Why?
|
Neoplasms, Second Primary | 1 | 2011 | 1051 | 0.060 |
Why?
|
Thrombocytopenia | 1 | 2011 | 1174 | 0.050 |
Why?
|
Injections, Intralymphatic | 1 | 2002 | 15 | 0.050 |
Why?
|
Peptides | 1 | 2015 | 4338 | 0.050 |
Why?
|
Stromal Cells | 3 | 2003 | 1330 | 0.050 |
Why?
|
Proportional Hazards Models | 3 | 2023 | 12429 | 0.050 |
Why?
|
Thrombolytic Therapy | 1 | 2011 | 2061 | 0.050 |
Why?
|
Adrenoleukodystrophy | 1 | 2024 | 143 | 0.050 |
Why?
|
Fibrinolytic Agents | 1 | 2011 | 2082 | 0.050 |
Why?
|
STAT1 Transcription Factor | 1 | 2023 | 340 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6471 | 0.050 |
Why?
|
Luminescent Proteins | 1 | 2004 | 836 | 0.050 |
Why?
|
Immunodominant Epitopes | 1 | 2022 | 240 | 0.050 |
Why?
|
Immunosuppressive Agents | 3 | 2011 | 4168 | 0.050 |
Why?
|
Pandemics | 1 | 2020 | 8623 | 0.040 |
Why?
|
Genes, Reporter | 1 | 2004 | 1528 | 0.040 |
Why?
|
Adenosine Deaminase | 1 | 2022 | 251 | 0.040 |
Why?
|
North America | 1 | 2024 | 1275 | 0.040 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2002 | 691 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2022 | 629 | 0.040 |
Why?
|
Prospective Studies | 6 | 2023 | 54339 | 0.040 |
Why?
|
Gene Fusion | 1 | 2022 | 354 | 0.040 |
Why?
|
Organ Size | 1 | 2004 | 2252 | 0.040 |
Why?
|
Mice, SCID | 1 | 2004 | 2625 | 0.040 |
Why?
|
Mice, Knockout | 2 | 2004 | 14397 | 0.040 |
Why?
|
Green Fluorescent Proteins | 1 | 2004 | 2060 | 0.040 |
Why?
|
Receptors, CXCR4 | 1 | 2003 | 727 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2014 | 7996 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 17854 | 0.040 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2000 | 899 | 0.040 |
Why?
|
Models, Immunological | 1 | 2000 | 512 | 0.040 |
Why?
|
Mice, Inbred C57BL | 4 | 2004 | 22121 | 0.040 |
Why?
|
Antibodies, Monoclonal | 3 | 2023 | 9176 | 0.040 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2022 | 1037 | 0.040 |
Why?
|
Follow-Up Studies | 5 | 2021 | 39078 | 0.040 |
Why?
|
Graft Survival | 3 | 2018 | 3806 | 0.040 |
Why?
|
Europe | 1 | 2024 | 3419 | 0.030 |
Why?
|
Genotype | 2 | 2023 | 12976 | 0.030 |
Why?
|
Thiotepa | 1 | 2016 | 66 | 0.030 |
Why?
|
Arabinonucleosides | 1 | 2016 | 34 | 0.030 |
Why?
|
Chronic Disease | 1 | 2011 | 9309 | 0.030 |
Why?
|
Adenine Nucleotides | 1 | 2016 | 111 | 0.030 |
Why?
|
Epitopes | 1 | 2022 | 2504 | 0.030 |
Why?
|
Neurotoxicity Syndromes | 1 | 2019 | 300 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2004 | 3777 | 0.030 |
Why?
|
Severity of Illness Index | 3 | 2021 | 15820 | 0.030 |
Why?
|
Microscopy, Confocal | 1 | 2021 | 1967 | 0.030 |
Why?
|
RNA Splicing | 1 | 2020 | 915 | 0.030 |
Why?
|
Blood Banks | 1 | 2016 | 108 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2020 | 640 | 0.030 |
Why?
|
Whole-Body Irradiation | 1 | 2016 | 433 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2004 | 2423 | 0.030 |
Why?
|
Blood Transfusion | 1 | 2022 | 1299 | 0.030 |
Why?
|
Flow Cytometry | 2 | 2004 | 5865 | 0.030 |
Why?
|
Mice, Transgenic | 2 | 2004 | 9533 | 0.030 |
Why?
|
Immunotherapy | 1 | 2010 | 4649 | 0.030 |
Why?
|
Exons | 1 | 2020 | 2392 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2017 | 10759 | 0.030 |
Why?
|
Immunity, Humoral | 1 | 2018 | 604 | 0.030 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2014 | 256 | 0.030 |
Why?
|
Colony-Forming Units Assay | 1 | 2014 | 352 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1790 | 0.030 |
Why?
|
Antigens, CD | 1 | 2004 | 4000 | 0.030 |
Why?
|
Antibodies, Neutralizing | 1 | 2023 | 1942 | 0.030 |
Why?
|
Age of Onset | 1 | 2020 | 3302 | 0.030 |
Why?
|
Dermatitis | 1 | 2015 | 200 | 0.030 |
Why?
|
Homeodomain Proteins | 1 | 2022 | 2413 | 0.030 |
Why?
|
Cell Communication | 1 | 2000 | 1652 | 0.030 |
Why?
|
Erythroid Precursor Cells | 1 | 2014 | 211 | 0.030 |
Why?
|
Homeostasis | 2 | 2001 | 3320 | 0.030 |
Why?
|
Siblings | 1 | 2017 | 825 | 0.030 |
Why?
|
Kinetics | 1 | 2020 | 6377 | 0.030 |
Why?
|
Transplantation, Autologous | 1 | 2017 | 2113 | 0.030 |
Why?
|
Trans-Activators | 1 | 2022 | 2858 | 0.030 |
Why?
|
Incidence | 2 | 2023 | 21322 | 0.020 |
Why?
|
Calcineurin | 1 | 2013 | 229 | 0.020 |
Why?
|
Budesonide | 1 | 2013 | 157 | 0.020 |
Why?
|
Protein Binding | 1 | 2004 | 9340 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2022 | 2803 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2020 | 4108 | 0.020 |
Why?
|
Interleukin-8 | 1 | 2014 | 696 | 0.020 |
Why?
|
Plant Lectins | 1 | 2011 | 103 | 0.020 |
Why?
|
Soybean Proteins | 1 | 2011 | 55 | 0.020 |
Why?
|
Stem Cells | 1 | 2004 | 3522 | 0.020 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2015 | 1351 | 0.020 |
Why?
|
Necrosis | 1 | 2015 | 1604 | 0.020 |
Why?
|
Rabbits | 1 | 2017 | 4780 | 0.020 |
Why?
|
Immunoglobulin Joining Region | 1 | 1990 | 37 | 0.020 |
Why?
|
Antibody Diversity | 1 | 1990 | 72 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2012 | 15627 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2015 | 2217 | 0.020 |
Why?
|
Vaccines, Attenuated | 1 | 2011 | 314 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2501 | 0.020 |
Why?
|
DNA Nucleotidyltransferases | 1 | 1990 | 176 | 0.020 |
Why?
|
Hemolysis | 1 | 2011 | 424 | 0.020 |
Why?
|
Genes, Immunoglobulin | 1 | 1990 | 285 | 0.020 |
Why?
|
Immunoglobulin Variable Region | 1 | 1990 | 419 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2004 | 18955 | 0.020 |
Why?
|
Genomics | 1 | 2024 | 5806 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2024 | 10425 | 0.020 |
Why?
|
Graft Rejection | 1 | 2021 | 4438 | 0.020 |
Why?
|
Time Factors | 3 | 2016 | 39947 | 0.020 |
Why?
|
Leukocyte Reduction Procedures | 1 | 2007 | 13 | 0.020 |
Why?
|
Skin | 1 | 2021 | 4474 | 0.020 |
Why?
|
Registries | 1 | 2024 | 8216 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2018 | 5491 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2004 | 9598 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2011 | 1832 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2023 | 14565 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2020 | 12054 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2012 | 2509 | 0.020 |
Why?
|
Antibodies, Bacterial | 1 | 2011 | 1469 | 0.020 |
Why?
|
DNA, Viral | 1 | 2011 | 2201 | 0.010 |
Why?
|
Cohort Studies | 2 | 2020 | 41366 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 2013 | 1874 | 0.010 |
Why?
|
Tacrolimus | 1 | 2007 | 733 | 0.010 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2006 | 694 | 0.010 |
Why?
|
Phenotype | 1 | 2020 | 16585 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2011 | 6086 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2013 | 3710 | 0.010 |
Why?
|
Venous Thrombosis | 1 | 2011 | 1297 | 0.010 |
Why?
|
Anemia | 1 | 2011 | 1508 | 0.010 |
Why?
|
Keratins | 1 | 2003 | 497 | 0.010 |
Why?
|
Lymphocytes | 1 | 1990 | 2610 | 0.010 |
Why?
|
Chemokines, CXC | 1 | 2003 | 422 | 0.010 |
Why?
|
Neutrophils | 1 | 2014 | 3764 | 0.010 |
Why?
|
United States | 2 | 2021 | 72202 | 0.010 |
Why?
|
Chemokine CXCL12 | 1 | 2003 | 454 | 0.010 |
Why?
|
Gene Expression | 1 | 2014 | 7582 | 0.010 |
Why?
|
Receptors, Chemokine | 1 | 2003 | 653 | 0.010 |
Why?
|
Signal Transduction | 1 | 2003 | 23397 | 0.010 |
Why?
|
Methotrexate | 1 | 2007 | 1720 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 12969 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2011 | 4549 | 0.010 |
Why?
|
Thrombosis | 1 | 2011 | 2940 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2007 | 6297 | 0.010 |
Why?
|
Anticoagulants | 1 | 2011 | 4806 | 0.010 |
Why?
|
Risk Assessment | 1 | 2017 | 23953 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2014 | 18216 | 0.010 |
Why?
|
Risk Factors | 2 | 2011 | 74055 | 0.010 |
Why?
|
Hematopoiesis | 1 | 2001 | 2049 | 0.010 |
Why?
|
VDJ Recombinases | 1 | 1990 | 84 | 0.010 |
Why?
|
Pregnancy | 1 | 2011 | 29831 | 0.010 |
Why?
|
Clone Cells | 1 | 1990 | 1660 | 0.000 |
Why?
|
Aged, 80 and over | 1 | 2011 | 58859 | 0.000 |
Why?
|
Gene Rearrangement | 1 | 1990 | 1125 | 0.000 |
Why?
|
Antineoplastic Agents | 1 | 2006 | 13616 | 0.000 |
Why?
|
Cell Line | 1 | 1990 | 15598 | 0.000 |
Why?
|